




























I. Sammendrag                           3 
II. Introduksjon                          4 
III. Metode og materiale                        7 
IV. Resultater                            7 
A. Effekter av telomerer og telomerase på aldring                7 
1. Dyreeksperimentelle studier                    7 
2.0 Humane studier                       8 




1. Kardiovaskulære sykdommer                21 
2. Kreft‐ og blodsykdommer                  29 
3. Autoimmune sykdommer                  39 
4. Progeroid syndrom                    41 
5. Demens og Alzheimers sykdom                45 
6. Andre sykdommer                    45 
C. Intervensjoner rettet mot telomerer og telomerase            47 
V. Konklusjon                          49 
VI. Litteraturliste                        50 
VII. Figurtekster                        54 
VIII. Ordliste                          58 


















































































































































































































































































































































































































































































producing cells was detected in patients and
controls (Table 2).
DISCUSSION
The present study was performed to investi-
gate whether mononuclear cells from patients on
maintenance hemodialysis therapy present fea-
tures of premature senescence. Our results show
that in these patients, 30% to 47% of mono-
nuclear cells fulfill the main characteristics of
senescent cells, which are short telomeres, in-
creased p53 expression, CD14dim/CD16bright
phenotype, and spontaneous cytokine produc-
tion.
Telomere length was assessed by means of the
FISH in flow cytometry technique, a method
validated by us and others.15,16 Our results show
that a significant percentage of mononuclear cells
from hemodialysis patients have short telomeres,
and the rest of the cells do not seem to be
affected. Thus, only a number of cells appear to
be senescent (short telomeres); this is not surpris-
ing because cells are renewed by those brought
into the circulation from bone marrow. Expect-
Fig 1. Telomere length measured by means of FISH in flow cytometry. (A) Telomere length in human mono-
nuclear cells from hemodialyzed patients and age-matched controls. (B) Representative histogram of telomere
fluorescence from a hemodialysis patient. Mononuclear cells were gated in region 1 (R1) on the basis of forward
versus side scatter (FSC versu SSC). Region 2 (R2; cells in G0/G1) were selected out from R1 according to FSC and
propidium iodide (PI) fluorescence. Telomere length was calculated by subtracting the mean background telomere
fluorescence from the mean fluorescence obtained with the telomere probe. Two different subsets of cells were




















































































































































































































































































during anaphase – the stage when chromosomes
move to opposite poles of the spindle during mito-
sis. This process leads to gains and losses of chro-
mosomal material in the daughter cells. In addition,
new breakpoints are generated that will induce an-
other round of fusion and breakage in the next
round of cell division. These “fusion-bridge-breakage
cycles” can contribute to the accumulation of CIN in
ageing human cells and thus to the accumulation of
genetic alteration leading to cellular transformation.
Studies in mTerc–/– mice have shown that loss of
checkpoint genes (specifically loss of p53) cooperates
with telomere dysfunction to induce CIN and cancer
initiation [41].
In contrast to the increase in chromosomal insta-
bility and tumour initiation, telomere shortening in-
hibits tumour progression and the formation of
macroscopic tumours in mTerc–/– mice [42]. Im-
paired tumour progression in telomere dysfunctional
mice co rela ed with an accumulation f high levels
of CIN and DNA damage in tumour cells, as well as
with impaired tumor cell proliferation and increased
rates of tumour cell apoptosis [42]. Together these
studies indicate that telomere shortening has a dual
role in caner. On the one hand it can increase the
initiation of tumours by inducing chromosomal in-
stability and genetic alterations that lead to cellular
transformation. On the other hand, tumour cells
need to stabilize telomere shortening to avoid an ac-
cumulation of too high levels of instability that
would ultimately kill the cancer cell (Fig. 1). This hy-
pothesis appears to be in line with the ob rvation
that most human cancers have critically short telo-
meres but at the same time show a reactivation of
telomerase (see above).
Conclusion
There is increasing evidence that telomere dysfunc-
tion has a causative role in human ageing, diseases,
and cancer. Understanding the pathways and check-
points that limit cellular function in response to telo-
mere dysfunction could point to molecular targets for
future therapies aiming to improve organ main-
tenance, regeneration and health in the growing
population of the elderly. Moreover, these check-
points are strongly connected to cancer formation
and could thus be targets for future anti-cancer
therapies. Telomere dysfunction and the activation
of downstream pathways could also be biomarkers
for human ageing and cancer risk. An investigation
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Table 3 Telomerase mutation and disease
Disease Mutation Publication
Adult-onset pulmonary fibrosis TERT Tsakiri KD et al., 2007
TERC Tsakiri KD et al., 2007
Idiopathic pulmonary fibrosis TERT Armanios MY et al., 2007
TERC Armanios MY et al., 2007
Bone marrow failure TERT Vulliamy TJ et al., 2005
Aplastic anaemia TERC Vulliamy et al., 2002
TERC Xin ZT et al., 2007
TERT Liang J et al., 2006
TERT Yamaguchi H et al., 2005
TERT Xin ZT et al., 2007
Autosomal dominant dyskeratosis TERC Vulliamy TJ et al., 2006
congenita (ADDC) TERC Armanios M et al., 2006
TERC Xin ZT et al., 2007
TERC Vulliamy T et al., 2004
TERC Goldman F et al., 2005
TERC Chen JL et al., 2004
TERC Wong JM et al., 2006
TERC Walne AJ et al., 2007
TERC Wong JM et al., 2006
TERC Ly H et al., 2005
TERC Cerone MA et al., 2005
TERC Knudson M et al., 2005
TERC Theimer CA et al., 2003
TERC Lin JH et al., 2002
TERC Vulliamy T et al., 2002
TERC Vulliamy T et al., 2001
TERC Mitchell JR et al., 1999
TERT Xin ZT et al., 2007
TERT Armanios M et al., 2005
MDS TERC Ly H et al., 2005
TERC Ohyashiki K et al., 2005
Cri-du-chat syndrome TERT Zhang et al., 2003

















Fig. 1 Telomere shortening has a dual role in cancer formation. Telomeres
shorten during ageing. In aged tissue a growing number of cells have short,
dysfunctional telomeres. As a consequence chromosomal instability (CIN) in-
creases, especially, when checkpoints genes are abrogated, such as p53. This
leads to an increase in tumour initiation during ageing. However, tumour cell
proliferation induces further telomere shortening and genetic chaos inhibiting
tumour cell survival and tumour progression. At this stage, the activation of
telomerase in tumour cells is required for tumour progression. Therefore, telo-
































































































































































merase activity. Modulators of mRNA expression of telomer-
ase components (i.e., hTERT) have been regarded as another
type of anti-telomerase agent. These include all-trans-retinoic
acid [6], 5,6-trans-16-ene-vitamin D3 [35], ceramide [36], and
curcumin [37]. These compounds act as suppressors of hTERT
mRNA expression, which result in altering telomerase activity
indirectly. Therefore, two model systems were used in the
present study to investigate the inhibitory effect of a series of
long-chain fatty acids on telomerase. A cell-free system was
used to evaluate the direct interaction of fatty acids with
telomerase, and the other, using cultured cells, assessed the
indirect effect of fatty acids on telomerase activity.
In the cell-free system, we demonstrated that fatty acids,
particularly PUFAs, directly inhibited telomerase derived from
human colorectal adenocarcinoma cells (DLD-1) (Figs. 1–4).
The following profiles, 1–8, for telomerase inhibition were
deduced by testing a series of fatty acids, that 1, the
telomerase-inhibitory potency of a fatty acid increases with
the number of double bonds; 2, cis-fatty acids have higher anti-
telomerase activities than trans-isomers; 3, cis-fatty acids with
the first double bond between carbon atoms 9 and 11 are more
potent inhibitors than those with double bonds occurring
earlier; 4, saturated fatty acids barely inhibit telomerase
activity; 5, cis-mono-fatty acids with a chain length of more
than C16 exhibit an inhibitory effect; 6, among cis-fatty acids
with an equal number of double bonds, shorter chain length is
more favorable for inhibition; 7, hydroxy-fatty acids are less
effective in telomerase inhibition than their corresponding fatty
acids which lack the hydroxyl group; 8, an esterified fatty acid
completely lost its anti-telomerase activity.
Contrary to the first result above 1, Oda et al. [38]
recently reported that oleic acid (18:1, D9cis) was the
strongest telomerase inhibitor among the fatty acids they
tested. They also mentioned that the rank order of effective
inhibitor was as follows: 18:1 D9cis >18:2 D9–12cis >18:3
D9 – 12 – 15cis = 18:3 D6 – 9 – 12cis > 18:4 D6 – 9 – 12 –
15cis > 16:1 D9cis > 20:1 D11cis > 22:1 D13cis = 12:1
D9cis =14:1 D9cis =24:1 D15cis. According to the authors’
paper, the principle for their assay of telomerase activity is
essentially similar to our present report, except for several
minor differences in the experimental conditions. Namely,
these authors assessed the effect of fatty acids dissolved in
DMSO on telomerase from human chronic myelogenous
leukemia cells (K562) using the modified telomeric repeat
amplification protocol (TRAP) assay with a fluorescence
capillary electrophoresis system. In contrast, we evaluated
the telomerase activity by the stretch PCR method using
DLD-1 lysate and fatty acids dissolved in ethanol. We
cannot explain the exact reasons for the contradictory results
obtained in the former study [38]. It is conceivable that the
fatty acids actually interact with telomerase, but the
compounds might also affect other enzymes and/or con-
taminants present in the cell lysate. For example, the
previous studies showed that 3V-azido-3Vdeoxythymidine
(AZT) inhibits telomerase activity in concentrations ranging
Fig. 5. Cellular telomerase activity is decreased by treatment with PUFAs. (A)
DLD-1 cells were cultured with fatty acids (EPA or DHA; 50 AM each) or
without sample (control) for 4 days. Subsequently, telomerase activity in the
cell extracts was measured by the stretch PCR assay. IS, internal standard. (B)
The time and dose dependence of telomerase inhibition was evaluated by
treating DLD-1 cells with 20–50 AM fatty acids (EPA or DHA) or without
sample (control) for 4 or 7 days. Telomerase activity is expressed as a
percentage of the control. *Telomerase activity could not be analyzed, since
cytotoxicity was observed after the cultivation of DLD-1 with 50 AM DHA for
7 days. Values are meansTS.D. from three independent experiments.
Fig. 6. Effect of EPA and DHA on the DLD-1 proliferation. DLD-1 cells grown
in 96-well plates were treated with 20–50 AM fatty acids (EPA or DHA) or
without sample (control) for 3 days. The viable cells were then evaluated by
MTT assay and are expressed as a percentage of the control. Values are
meansTS.D. from five independent experiments.
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from 100 AM to 1.75 mM, according to the IC50
(concentration showing 50% inhibition of the enzymatic
activity) for the cell lines used [39]. Furthermore, AZT
triphosphate inhibits telomerase in leukemic blast cells (30
AM) and in CHO cells (500 AM) [40]. These results clearly
indicate that the inhibitory potency of telomerase would
depend on the cell types used in a cell-free system. Further
studies using the purified enzyme would be needed to fully
clarify the inhibitory strength of fatty acids on telomerase.
Compared with telomerase, considerable information is
available concerning the structure and function of human
immunodeficiency virus-type 1 reverse transcriptase (HIV-1
RT). The three-dimensional structure of HIV-RT can be
described as a right hand, with subdomains referred to as the
fingers, palm and thumb [41]. Highly conserved regions are
located in the palm subdomain near the polymerase active site.
These structural elements of the palm and the two a-helices of
the thumb act as a clamp to position the template-primer
relative to the polymerase active site [42]. HIV-1 RT has been
successfully inhibited by two major classes of inhibitors, chain-
terminating nucleoside analogs which bind to the dNTP site
[43], and non-nucleoside RT inhibitors (NNRTI) which bind to
a hydrophobic pocket near the catalytic center resulting in a
distortion of the active site [41,44]. The NNRTI nevirapine, for
example, preferentially inhibits the translocation step of
polymerization [41], and co-crystallization experiments
revealed that it binds into a deep hydrophobic pocket lying
between the h-sheets of the palm and the base of the thumb
close to the template primer terminus [41].
Previous studies [45,46] have shown that TERT exhibits
significant homology to RT, and so key features in their
structure and b sic mecha ism of catalysis appear similar. For
example, it has been shown that point mutations in amino acids
that are conserved between TERT and retroviral RT (i.e., Lys443
and Arg450 in TERT, and Lys65 and Arg72 in RT) reduced or
abolished activity in both enzymes [45]. Hence, telomerase
would contain hydrophobic pockets that lie between the palm
and thumb, which might be targeted by small molecule
inhibitors [46].
On the basis of these previous observations [45,46], we
speculated on the inhibitory mechanism of fatty acids on
telomerase activity. Since hydroxy-fatty acids exhibited weaker
inhibition than fatty acids without a hydroxyl group (Fig. 4A),
the hydrocarbon chain of fatty acids may interact with
hydrophobic pockets of telomerase. Generally, the hydrocarbon
chain of the saturated and trans-unsaturated fatty acids is
linear, while that of the cis-unsaturated fatty acids forms a
round shap with an incre sed number f double bonds.Fig. 7. Inhibitory effect of EPA and DHA on mRNA expression of hTERT and
c-myc and on cellular PKC activity. DLD-1 cells were cultured with 20–50 AM
fatty acids (EPA or DHA) or without sample (control) for 4 or 7 days. The
mRNA expression levels of hTERT (A) and c-myc (B) were then measured by
real-time RT-PCR and is expressed as a percentage of the control. The mRNA
level of h-actin was used as an internal control. (C) PKC activity in the cell
extracts was then evaluated by the stretch PCR assay. Values are meansTS.D.
from three independent experiments. *Expression of hTERT and c-myc mRNA
and PKC activity could not be analyzed, since cytotoxicity was observed after
the cultivation of DLD-1 with 50 AM DHA for 7 days.
Fig. 8. A mechanism for telomerase inhibition by EPA and DHA in a cell
cult re experiment.
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normalen Alterungsprozess. Das
am wenigsten bekannte Chromo-
somenbruchsyndrom ist die Fan-
coni-Anämie, welche durch bialle-
lische Mutationen in einem von
zumindest 13 verschiedenen
DNA-Reparaturgenen, darunter
das BRCA2-Gen, verursacht wird.
Die Fanconi-Anämie ist die einzi-
ge Erkrankung des Menschen, de-
ren Zellen eine konstitutionelle
Überempfindlichkeit gegen oxida-
tiven Stress aufweisen. Die Validi-
tät der freien Radikal-Theorie des
Alterns lässt sich daher anhand
der Fanconi-Anämie erstmals








Ageing can be defined as loss of homeostasis that af-
fects all structural, metabolic, neuroendocrine, im-
munologic and genomic maintenance systems of our
body [4]. From a genetic point of view, loss of ge-
netic homeostasis appears as a key factor that con-
tributes to ageing in cells and organisms. Loss of ge-
netic stability and nuclear integrity leads to cellular
and organismal dysfunction, and to the emergence
of malignant cell growth as a possible endpoint of
accumulated alterations. Much of what we currently
know about the intimate connection between loss of
genetic homeostasis and the premature occurrence
of cancer and ageing derives from the meticulous
study of rare human syndromes that are caused by
defects in DNA and chromatin maintenance systems
[32]. As depicted in Figure 1, manifestations of these
individually rare “experiments of nature” may be ob-
served at the chromosomal, telomere or nuclear en-
velope levels. In this brief review we will discuss
some of the human genetic instability syndromes,
emphasizing the connection between genetic insta-
bility, cancer, and ageing. The classical progerias,
Hutchinson-Gilford syndrome and Werner syndrome
will be mentioned only briefly, since there are a
number of excellent reviews dealing with these well-
known disorders (e.g.[9]). We will also exclude from
our discussion primary immunodeficiency disorders
associated with defective DNA double-strand repair
[3], as these disorders are not primarily character-
ized by instabilities at the chromosomal, telomeric
or nuclear membrane levels. Instead, we will devote
more space and emphasis to the discussion of Fan-
coni anemia (FA). FA is a less well-known human
genetic instability syndrome which displays a num-
ber of features that are reminiscent of accelerated
ageing.
Laminopathies as paradigms
of impaired nuclear stability
In mammalian cells, integrity and shape of the nu-
clear envelope is maintained by A-type lamins,
members of intermediate type filament proteins
which also form part of the nuclear matrix scaffold.
Chromosomal telomeres are attached to the inner
nuclear lamina. There are multiple interactions be-
tween chromatin and the nuclear matrix such that
lamin A/C defects are thought to impair various nu-
clear functions including chromatin and chromo-
some stability, telomere integrity, regulation of tran-
scription, DNA replication, cell cycle control, and
cellular differentiation [9]. Dominant missense muta-
tions in LMNA, the gene coding for Lamin A/C, have
been recognized as the cause of at least ten different
disease entities, collectively referred to as “lamino-
pathies”. This group of diseases includes examples
of muscular dystrophies, cardiomyopathies, lipody-
strophies, neuropathies, and, most prominently, the
Hutchinson-Gilford juvenile progeria (HGP) syn-
drome. Of interest to the gerontologist are additional




  breakage 
      syndromes
Lamin A/C
Laminopathies
Fig. 1 Major groups of nuclear instability syndromes provoking progeroid
features in humans. Chromosome breakage syndromes are caused by defects
in DNA-maintenance genes. Laminopathies arise due to dysfunctions of lamin
A/C as a major component of the inner nuclear lamina and nuclear matrix.
Mutational inactivation of Dyskerin or the RNA-component of telomerase
(TERT) cause excessive telomere shortening and telomere dysfunction in Dys-
keratosis congenita. See text for details
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telomerforkortning via økt kompensatorisk celleomsetning, eller via direkte 
effekt på telomerisk DNA (tDNA) (2). 
Hutchinson‐Gilford Progeriasyndrom (HGPS) er en sykdom som fører til 
ekstremt rask aldring. Årsaken til den svært raske aldringen skyldes en 
mutasjon Lamin A‐genet (LMNA). Dette fører til et mutert Lamin‐A‐protein 
kjent som progerin. Progerin fins i små mengder også hos mennesker uten 
HGPS. Det er antatt at telomerskade spiller en rolle når det kommer til å 
aktivere progerinproduksjonen (30). Sykdommen rammer 1/4‐8 millioner 
barn. Symptomer ligner dem på normal aldring, slik som tynn hud, tap av 
subkutant vev, hårtap, stive ledd, osteoporose og kardiovaskulær sykdom. 
Personer som er rammet av sykdommen blir i gjennomsnitt 13 år gamle og 
dør av hjerteinfarkt eller slag. En av de cellulære defektene hos personer 
med HGPS er korte telomerer. I en studie ble det undersøkt om telomerase 
kunne hindre den premature aldringen av cellene hos personer med HGPS. 
Retroviral TERT ble infisert i fibroblaster affisert av HGPS som var på slutten 
av sitt proliferative potensiale (to gjenstående populasjonsdoblinger).  
Cellegruppen som fikk infisert TERT viste ingen tegn til nedgang i 
proliferativ kapasitet etter 70 populasjonsdoblinger, mens cellegruppen 
som ikke fikk infisert TERT, stoppet å proliferere etter to 
populasjonsdoblinger.  På tross av tilsynelatende økt 
celledelingspotensiale, sank ikke nivået av progerin i cellene som fikk 
infisert TERT. Det viste seg også at TERT‐infiserte fibroblaster hadde lavere 
aktivitet i p53‐ og retinoblastom‐tumorsupressorveiene. Dersom DNA‐et 
skades, kan p53 initiere apoptose, stoppe cellesyklus og aktivere DNA‐
reparasjonsproteiner. Retinoblastom (Rb) hindrer skadet DNA i å replikere 
seg. Effekten av p53 og Rb ble undersøkt, og i fibroblaster som var nær 
slutten av sitt celledelingspotensiale ble disse to hemmet. Dette førte til 68 
populasjonsdoblinger. Progerin induserer DNA‐skade.  DNA‐skade 
induserer aktivering og/eller fosforylering av proteiner om er involvert i 
DNA‐skaderesponsen. Disse proteinene samles i områder med DNA‐skade 
og er i så måte gode indikatorer på nettopp dette. HGPS‐fibroblaster har 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økt DNA‐skadesignalering. I fibroblaster infisert med TERT var det langt 
færre områder i DNAet med aggregering av nettopp slike proteiner. Dette 
indikerer at TERT hindrer progerinets DNA‐skadelige effekter. Hvordan 
progerinet fører til telomerdysfunksjon er ikke kartlagt, men det er ting 
som tyder på at det progerinet fører til dysfunksjon i et enzym, histon 
deacetylase, som er viktig i reguleringen av DNA‐replikasjonen og som 
modulerer telomerkromatinstrukturen. Dette fører til raskere cellealdring 
og DNA‐skadesignalering på telomerene (31). 
En rekke andre aldringssykdommer har vært mer direkte relatert til 
telomerdysfunksjon. Blant disse er Fanconianemi (FA) og ataxia 
telangiektasia (AT), som begge er autosomal recessive sykdommer. FA 
skyldes mutasjon i ett av minst 12 forskjellige Fanconigener (som koder for 
Fanconianemikomplementeringsgruppeprotein), mens AT skyldes ataxia 
telangiektasiamutert gen (som koder for ATM‐proteinet). Felles for disse 
proteinene er at de er delaktig i DNA‐skade‐ og reparasjonssystemet. 
Begge sykdommer er assosiert med akselerert telomerforkortning. Avvik i 
telomerreplikasjon‐ eller reparasjon antas å spille en viktig rolle i 
patogenesen, spesielt i utvikling av sykdommer som skyldes immundefekt 
eller benmargssvikt, så vel som økt predisposisjon for malignitet hos unge 
voksne (2). 
I motsetning til celler fra enhver annen human sykdom, er FA‐celler unikt 
sensitive for oksidativt stress. I en situasjon med defekt DNA‐reparasjon, vil 
oksidativt stress lede til akkumulering av DNA‐skade. Oksidativt stress er 
den sannsynlige årsaken til benmargssvikt, neoplasi og prematur aldring i 
FA, og denne sjeldne sykdommen er dermed den eneste kjente humane 
modellen for teorien om frie radikalers effekt på aldring (29). 
Dyskeratosis congenita (DC) er en sjelden multisystemsykdom, som 
eksemplifiserer viktigheten av telomerintegritet for en mengde 
tilsynelatende ikke‐relaterte cellulære funksjoner. Den X‐bundne formen 
av DC skyldes en mutasjon i dyskeringenet (DKC1), som er assosiert med 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RNA‐komponenten til telomerasekomplekset (TERC). Den autosomale 
dominante formen for DC har vist seg å stamme fra mutasjon i selve TERC 
(Figur 22). Pasienter med DC har derfor vist homogent reduserte nivåer av 
TERC, og som følge av svekket telomerasefunksjon, har de kortere 
telomerer enn sine jevngamle kontroller. Mens unormal hudpigmentering, 
negldystrofi og leukoplaki utvikles i barne‐ og ungdomsårene, vil voksne 
pasienter kunne ha gastrointestinale, geniuretrale, nevrologiske, lunge‐ og 
skjelettmisdannelser. Den mest alvorlige komplikasjonen er likevel at 80‐90 
% utvikler pancytopeni på grunn av benmargssvikt i 30 års alder og økt 
risiko for malignitet. Pasienter med DC viser derfor en rekke progeroide 
kjennetegn, noe som kan tyde på en kausal sammenheng mellom korte 
telomerer og prematur aldring. TERC‐mutasjoner har også blitt observert 
sporadisk hos pasienter uten typiske DC‐kjennetegn, inkludert 
undergrupper av aplastisk anemi, myelodysplastisk syndrom og paroxysmal 
nattlig hemoglobinuri, som alle er stamcellesykdommer (29). 
 
Figur 22 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5. Demens og Alzheimers sykdom 
Pasienter med Alzheimer har unormalt korte telomerer i lymfocytter, 
sammenlignet med ikke Alzheimer‐kontroller. I en studie ble denne 
hypotesen testet. Personer med Alzheimers ble sammenliknet for 
telomerlengde i monocytter.  Telomerlengden hos personer med 
Alzheimers var 6,6 ± 0,2 kb, mens den hos friske (kontrollgruppe) var 
7,3 ± 0,2 kb, p<0,05. For personer med mild kognitiv svikt, var det ingen 
statistisk forskjell sammenliknet med kontrollgruppen. Det var ingen 
sammenheng mellom telomerlengde og MMS‐score (mini mental state 
examination) (4, 32). 
Telomerlengde kan, som det er for biologisk alder, være en biomarkør for 
demens. I en studie gjort på 62 kvinnelige sykepleiere ble det funnet en 
kraftig økning i risiko for utvikling av kognitiv svikt hos dem med korte 
telomerer. Odds ratio for utvikling av demens/mild kognitiv svikt eller mild 
kognitiv svikt var henholdsvis 9,63 ganger så høy (95 % KI 1,73–53,65) og 
12 ganger så høy (95 % KI 1,24–116,5). Det var også en statistisk signifikant 
sammenheng mellom kort telomerlengde og liten hippocampus. For hver 
T/S‐ratioenhet mindre var hippocampus 25 ml mindre (p=0,038) (33). 
Hippocampus er viktig for blant annet lagring av langtidsminnet (34). 
6. Andre sykdommer 
Telomerforkortning har blitt observert i lymfocytter ved kronisk HIV‐
infeksjon, i hepatocytter ved kronisk hepatitt, i intestinalt epitel ved kronisk 
inflammatorisk tarmsykdom, i forskjellig former for anemi, i lymfocytter 
hos Alzheimerpasienter og i vaskulære endotelceller i aterosklerotisk plakk. 
Ytterligere synes telomerforkortning å korrelere med 
sykdomsprogresjonen i enkelte sykdommer. Et eksempel på dette er 
levercirrhose, som utvikles i endestadiet av kronisk leversykdom. En modell 
indikerer at kronisk hepatocyttskade leder til økt hepatocyttomsetning og 
akselerert telomerforkortning. Kritisk korte telomerer vil da føre til 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hepatocyttaldring, som fremmer utviklingen av levercirrhose karakterisert 
ved redusert regenerativ reserve, fibrotisk arrvev og organsvikt. I samsvar 
med denne modellen, korrelerer telomerforkortning med utvikling og 
progresjon av levercirrhose (4). Nyere studier har vist at mutasjoner i 
genene som koder for telomerasekomponenter, er også implisert i familiær 
idiopatisk pulmonal fibrose (2). 
I en studie ble telomerlengden hos 68 pasienter med schizofreni undersøkt. 
På bakgrunn av hvordan de reagerte på antipsykotisk medisinering ble de 
delt inn i grupper, såkalte ”good responders” og ”poor responders”, 34 i 
hver gruppe. Disse ble sammenliknet med 76 friske personer. Som mål på 
telomerlengde ble TRF (i kb) brukt. For ”good responders” var TRF 8,88 
med standardavvik (SD) på 0,90, for ”poor responders” var TRF 7,41 med 
SD på 0,97, for friske var TRF 8,91 med SD 1,35. Det var statistisk signifikant 
forskjell mellom ”poor responders” og friske, p<0,001 (35). 
I en studie ble 21 type 2‐diabetikere sammenlignet med 29 friske personer. 
Hos diabetikerne var telomerene i monocytter signifikant kortere enn hos 
friske individer (4,0 mot 5,5 kb, p<0,0001). Hos diabetikerne var det et 
invertert forhold mellom telomerlengden i perifere mononukleære 
blodceller og mengde oksidativ DNA‐skade (r=‐0,55, p=0,018) (Figur 23), 
noe som tyder på at type 2‐diabetikere er mer utsatt for oksidativt stress. 
Oksidativt stress angriper, som tidligere beskrevet, GGG‐sekvenser i 
telomerene, og fører så til forkorting av telomerene (se under 
kardiovaskulære sykdommer) (36). 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Figur 23 
C. Intervensjoner rettet mot telomerer og telomerase 
Intervensjoner rettet mot telomerer og telomerase har vært gjenstand for 
mange forskningsprosjekter de siste årene, og noen applikasjoner blir nå 
utforsket i kliniske utprøvninger (2). 
Strategier for å redde humane celler in vitro fra biologisk aldring, eller 
forlenge deres livsløp ved å uttrykke ektopisk telomerase, ble først 
beskrevet for over et tiår siden og er nå rutinemessig brukt i mange 
laboratorier for å forlenge levetiden til primære humane celler. Denne 
tilnærmingen appellerer også til terapi av celler eller vev, ettersom antall 
tilgjengelige celler ofte er begrenset. Selv om ektopisk uttrykk av TERT 
fortsatt er på et utviklingsstadium, har signifikante fremskritt allerede blitt 
gjort for å forsterke allografter og konstruere vev for transplantasjon. 
Denne typen tilnærming kan også være nyttig for spesifikke T‐
celleimmunoterapiprotokoller, der spesifikke T‐celler gjenkjenner 
spesifikke antigener (antigener spesifikke til melanomceller eller HIV‐virus) 
for deretter å bli renset, ekspandert in vitro og infusert i pasienter. Ektopisk 
uttrykk av TERC og TERT i fibroblaster fra DC‐pasienter har vist seg å redde 
disse cellenes proliferative egenskaper, og man kan tenke seg at 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tilsvarende strategi kan brukes i behandling av beinmargssvikt knyttet til 
mutasjon i telomerasegenet (2). 
Hemming av telomeraseaktivitet er også et svært spennende område for 
telomerintervensjoner, da de fleste krefttilfeller uttrykker telomerase. 
Imidlertid gjør uklarheter rundt toksisitet, halveringstid, 
administrasjonsformer, samt lang tidsforsinkelse for å oppnå død av 
kreftceller både in vivo og in vitro, at det fortsatt gjenstår problemstillinger 
som kan svekke terapeutisk suksess. Andre former for 
antitelomerasekreftterapi tar sikte på å utnytte og å styrke 
immunresponsen til telomerase (TERT) gjennom vaksinasjonsliknende 
tilnærminger. Høyere nivåer av TERT‐protein uttrykkes i mange kreftceller, 
og TERT‐epitoper kan bearbeides og presenteres av antigenpresenterende 
celler til antigenspesifikke T‐celler som igjen dreper målcellene. Denne 
gjenkjenningen av TERT‐positive kreftceller er kjent for aktivt å forårsake 
kreftcelledød mye raskere enn andre strategier, der progressiv 
telomerforkortning må finne sted (2). 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V. Konklusjon 
Det er økende bevis for at korte telomerer og telomerdysfunksjon har en 
viktig rolle i humane sykdommer og bidrar til aldring. For å opprettholde 
telomerlengde, er enzymet telomerase helt essensielt. Studier på pasienter 
med telomerasemutasjoner understreker viktigheten av telomerlengde, da 
disse pasientene viser multiple tegn på prematur aldring og sykdom. Med 
økende alder blir telomerene kortere, og evnen til cellereproduksjon går 
ned. Dette er nødvendigvis ikke en dårlig ting, da redusert celledeling i 
aldrende celler virker som en forsvarsmekanisme mot kreftutvikling. 
Dessverre vil telomermekanismene som begrenser vekst av premaligne 
celler, også besørge sterk seleksjon av celler som ikke lenger responder på 
DNA‐skademekanismene med aldring som resultat. Ved å forstå hvilke 
faktorer som begrenser cellulære funksjoner som respons på 
telomerdysfunksjon, vil man kanskje i fremtiden kunne finne molekylære 
mål for behandling, som tar sikte på å forbedre opprettholdelse og 
regenerasjon av organer, samt forbedre helse i den voksende, eldre 
befolkningen. To store intervensjonsspørsmål rettet mot telomerer det 
forskes mye på er om det er mulig å kurere kreft ved å deaktivere 
telomerase, og om man kan forhindre aldring ved å aktivere telomerase. 
Hvis forskere kan aktivere enzymet telomerase i hele kroppen til eldre 
mennesker, kan man tenke seg at cellereplikasjon igjen finner sted, men 
med fare for utvikling av kreft.  
 
 
 
 
 
  50 
VI. Litteraturliste 
1. Landmark K sr., Landmark K jr., Haarr H. Omega‐3‐fettsyrer, telomerer, 
telomerase og kardiovaskulær sykdom. Hjerteforum. 2011;24: 64‐67.  
2. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008 
Apr;88(2):557‐79. 
3. Bekaert S, De Meyer T, Rietzschel E, et al. Telomere length and 
cardiovascular risk factors in a middle‐aged population free of overt 
cardiovascular disease. Aging cell. 2007;6:639‐647. 
4. Jiang H, Ju Z, Rudolph K. Telomere shortening and ageing. Z Gerontol 
Geriatr. 2007;40:314‐324. 
5. Alberts B, Bray D, Hopkin K, et al. Essential cell biology. 2th ed. New 
York and London: Garland Science; 2004. 
6. Fuster J, Andres V. Telomere biology and cardiovascular disease. 
Circulation Research. 2006;99:1167‐1180. 
7. Rana A, Metzger P. OpenPit Blog [Internet]. USA: Aditya Rana. [cited 
2009 Oct 12]. Available from: 
http://openpit.wordpress.com/2009/10/12/immortality/ 
8. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing 
of human fibroblasts. Nature. 1990 May 31;345(6274):458‐60. 
9. De Meyer T, Rietzschel ER, De Buyzere ML, et al. Studying telomeres in 
a longitudinal population based study. Front Biosci. 2008 Jan 
1;13:2960‐70. 
10. SSB.no [Internet]. Statistisk sentralbyrå. [cited 2011]. Available from: 
http://www.ssb.no/befolkning/forventet.cgi 
11. Cawthon RM, Smith KR, O'Brien E, et al. Association between telomere 
length in blood and mortality in people aged 60 years or older. Lancet. 
2003 Feb 1;361(9355):393‐5. 
12. Ramírez R, Carracedo J, Soriano S, et al. Stress‐induced premature 
senescence in mononuclear cells from patients on long‐term 
hemodialysis. Am J Kidney Dis. 2005 Feb;45(2):353‐9. 
  51 
13. Brouilette S, Singh R, Thompson J, et al. White Cell Telomere Length 
and Risk of Premature Myocardial Infarction. Arteriosclerosis, 
Thrombosis, and Vascular Biology. 2003;23:842‐846. 
14. Farzaneh‐Far R, Cawthon R, Na B, et al. Prognostic value of leukocyte 
telomere length in patients with stable coronary artery disease: data 
from the Heart and Soul Study. Arteriosclerosis, Thrombosis, and 
Vascular Biology. 2008;28:1379‐1384. 
15. Chang E, Harley CB. Telomere length and replicative aging in human 
vascular tissues. Proc Natl Acad Sci USA. 1995 Nov 21;92(24):11190‐4. 
16. Ogami M, Ikura Y, Ohsawa M, et al. Telomere shortening in human 
coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular 
Biology. 2004;24:546‐550. 
17. Satoh M, Minami Y, Takahashi Y, et al. Effect of intensive lipid‐lowering 
therapy on telomere erosion in endothelial progenitor cells obtained 
from patients with coronary artery disease. Clinical Science (London). 
2009 May 1;116(11):827‐35. 
18. Benetos A, Okuda K, Lajemi M. Telomere length as an indicator of 
biological aging: the gender effect and relation with pulse pressure and 
pulse wave velocity. Hypertension. 2001 Feb;37(2 Part 2):381‐5. 
19. Farzaneh‐Far R, Lin J, Epel ES, et al. Association of marine omega‐3 
fatty acid levels with telomeric aging in patients with coronary heart 
disease.  JAMA. 2010 Jan 20;303(3):250‐7. 
20. Li A, Lin H, Kuo C, et al. High‐mobility group A2 protein modulates 
hTERT transcription to promote tumorigenesis. Molecular and Cellular 
Biology. 2011 Jul;31(13):2605‐2617. 
21. Willeit P, Willeit J, Mayr A, et al. Telomere length and risk of incident 
cancer and cancer mortality. JAMA. 2010 Jul 7;304(1):69‐75. 
22. Engelhardt M, Mackenzie K, Drullinsky P, et al. Telomerase activity and 
telomere length in acute and chronic leukemia, pre‐ and post‐ex vivo 
culture. Cancer Research. 2000 Feb 1;60(3):610‐7. 
23. Stefanou N, Papanikolaou V, Furukawa Y, et al. Leptin as a critical 
regulator of hepatocellular carcinoma development through 
  52 
modulation of human telomerase reverse transcriptase. BioMed 
Central Cancer. 2010;10:442. 
24. Calado R, Yewdell W, Wilkerson K, et al. Sex hormones, acting on the 
TERT gene, increase telomerase activity in human primary 
hematopoietic cells. Blood. 2009 September 10;114(11):2236–2243. 
25. Eitsuka T, Nakagawa K, Suzuki T, et al. Polyunsaturated fatty acids 
inhibit telomerase activity in DLD‐1 human colorectal adenocarcinoma 
cells: a dual mechanism approach. Biochim Biophys Acta. 2005 Oct 
15;1737(1):1‐10. 
26. Goronzy J, Shao L, Weyand C. Immune aging and rheumatoid arthritis. 
Rheum Dis Clin North Am. 2010 May;36(2):297‐310. 
27. Fujii H, Shao L, Colmegna I, et al. Telomerase insufficiency in 
rheumatoid arthritis. Proc Natl Acad Sci (PNAS) USA. 2009 Mar 17;106 
(11):4360‐5. 
28. Kawashima M, Kawakita T, Maida Y, et al. Comparison of telomere 
length and association with progenitor cell markers in lacrimal gland 
between Sjögren syndrome and non‐Sjögren syndrome dry eye 
patients. Molecular Vision. 2011;17:1397‐404.  
29. Neveling K, Bechtold A, Hoehn H. Genetic instability syndromes with 
progeroid features. Z Gerontol Geriatr. 2007;40:339‐48. 
30. Cao K, Blair CD, Faddah DA, et al. Progerin and telomere dysfunction 
collaborate to trigger cellular senescence in normal human fibroblasts. 
The Journal of Clinical Investigation. 2011 July;121(7):2833‐44. 
31. Benson E, Lee S, Aaronson S. Role of progerin‐induced telomere 
dysfunction in HGPS premature cellular senescence. Journal of Cell 
Science. 2010 august;123:2605‐2612. 
32. Hochstrasser T, Marksteiner J, Humpel C. Telomere length is age‐
dependent and reduced in monocytes of Alzheimer patients. Exp 
Gerontol. 2012 Feb;47(2):160‐3. 
33. Grodstein F, van Oijen M, Irizarry MC, et al. Shorter telomeres may 
mark early risk of dementia: preliminary analysis of 62 participants 
from the nurses' health study. PLoS One. 2008 Feb 13;3(2):e1590.33. 
  53 
34. Brodal P. Sentralnervesystemet. 3rd ed. Oslo: Universitetsforlaget; 
2001. 
35. Yu W, Chang H, Lin C, et al. Short telomeres in patients with chronic 
schizophrenia who show a poor response to treatment. Journal of 
Psychiatry and Neuroscience. 2008 May;33(3):244‐7. 
36. Sampson MJ, Winterbone MS, Hughes J. Monocyte telomere 
shortening and oxidative DNA damage in type 2 diabetes. Diabetes 
Care. 2006 Feb;29(2):283‐9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  54 
VII. Figurtekster 
Figur 1: øverste figur viser hvordan primeren (grønn strek) festes til 
henholdsvis ”leading” og ”lagging strand” og hvordan basene primeren på 
”leading strand” fester seg til ikke vil replikeres.  
Figur 2: figuren viser at bestemte proteiner binder seg til telomerene, og 
bestemmer telomerfunksjon ved å regulere telomerlengde og ‐struktur. A: 
telomeren er lukket og dermed ikke tilgjengelig for telomerase. B: 
telomeren er åpen og TTP1 og POT1 rekrutterer og stimulerer enzymatisk 
telomeraseaktivitet, fortrinnsvis hos kromosomender med korte telomerer. 
Figur 3: figuren viser redusert mengden telomerisk DNA under gjentatt 
replikasjon hos humane fibroblaster i kultur. Gjennomsnittlig 
telomerlengde (a) og totalt telomerisk DNA (b) er vist som en funksjon av 
alder in vitro. 
Figur 4: figuren viser faktorer som påvirker telomerlengde i humane celler. 
Når telomerene blir for korte som følge av replikasjon eller oksidativt 
stress, vil de gjenkjennes av DNA‐reparasjonssystemet. Avhengig av 
celletype og gener som uttrykkes i cellen, kan enkelte korte telomerender 
forlenges av telomerase eller ved rekombinasjon. Når cellen akkumulerer 
for mange korte telomerender, vil DNA‐skadesignaler som p53 aktiveres og 
cellen vil gå inn i cellulær aldring eller apoptose. Dersom cellen ikke 
aktiverer disse DNA‐skadesignalene, vil cellen akkumulere genetisk 
instabilitet med kreftutvikling som ytterste konsekvens. 
Figur 5: figurene viser sammenhengen mellom telomerlengde i blod‐DNA 
og overlevelse. Den mørke linjen illustrerer individer med telomerlengde i 
øvre halvdel, og stiplet linje illustrerer de i nedre halvdel. 
Figur 6: figuren viser telomerlengde i humane mononukleære blodceller fra 
hemodialysepasienter og jevnaldrende kontroller. 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Figur 7: figuren viser hvordan TRF‐lengde synker fra venstre mot høyre og 
sammenhengen med Odds Ratio for hjerteinfarkt i tidlig alder. 
Figur 8: figuren viser redusert lengde av terminalt restriksjonsfragment 
(TRF) med økt donoralder i intimaceller i arteria thoracica interna (hvit) og 
arteria iliaca (svart). 
Figur 9: figuren demonstrerer mengdeforskjellen mellom telomerisk og 
centromerisk DNA hos friske (A) og personer med koronarsykdom (B) og 
således hvordan T/C‐ratio kan beregnes.  
Figur 10: A viser sammenhengen mellom pulsbølgehastighet og TRF‐lengde 
hos menn og kvinner. B viser sammenhengen mellom pulstrykk og TRF‐
lengde hos menn og kvinner. 
Figur 11: figuren viser sammenhengen mellom endring i telomerlengde 
(uttrykt som T/S‐enheter) og nivå av omega‐3‐fettsyrer.  
Figur 12: figuren viser rollen til telomerforkortning på kreftutvikling. I 
aldrende vev har et økende antall celler kritisk korte og dysfunksjonelle 
telomerer. Som en konsekvens øker den kromosomale instabiliteten (CIN), 
spesielt når effekten av sjekkpunktgener som p53 er opphevet. Dette leder 
til en økning i kreftinitiering ved aldring. Imidlertid vil proliferasjon av 
kreftceller indusere ytterligere telomerforkortning og genetisk kaos, som 
vil hemme overlevelse av kreftceller. På dette stadiet er aktivering av 
telomerase i kreftcellene nødvendig for kreftprogresjon.  
Figur 13: figuren viser sammenhengen mellom celler med og uten HMGA2 
og nivå av TERT. 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Figur 14: figuren viser sammenhengen mellom telomeraseaktivitet hos 
friske og hos personer med forskjellige blodsykdommer (HD = friske 
donorer, PV = polycythemia vera, CLL = kronisk lymfatisk leukemi, CML = 
kronisk myelogen leukemi, MDS = myelodysplastisk syndrom, AML = akutt 
myelogen leukemi). Stjerne angir statistisk økt telomeraseaktivitet.  
Figur 15: figuren viser forskjell i leptinnivå og uttrykk av leptinreseptorer 
(OB‐RI og OB‐Rs) hos friske og hos personer med hepatocellulært karsinom 
(HCC). Stjerne angir statistisk signifikant forskjell.  
Figur 16: figuren viser sammenhengen mellom økning i uttrykk av TERT‐
mRNA‐nivåer og nivåer av leptin administrert. Stjerne angir statistisk 
signifikant økning.  
Figur 17: figuren viser sammenhengen mellom økningen i 
telomeraseaktiviteten og mengde av og hvilket androgen som ble 
administrert. Stjerne/stjerner angir statistisk signifikant økning.   
Figur 18: figuren viser hvordan telomeraseaktivitet inhiberes i DLD‐1‐celler 
ved tilstedeværelse av fettsyrene EPA og DHA i forskjellige doser i 4 og 7 
dager. Stjerne indikerer at telomeraseaktiviteten ikke kunne analyseres på 
grunn av cytotoksisitet. 
Figur 19: figuren beskriver mekanismen for telomerasehemming av EPA og 
DHA i et cellekultureksperiment. 
Figur 20: figuren viser forskjell i telomeraseaktivitet etter induksjon i 
forskjellige T‐celler hos friske (grå søyler) og personer med reumatoid 
artritt (sorte søyler). 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Figur 21: figuren viser ulike kjerneinstabilitetssyndromer som forårsaker 
progeroide kjennetegn hos mennesker. Chromosome brakeage syndrom, 
laminopatier som Hutchinson‐Gilford Progeriasyndrom og Dyskeratosis 
congenita, er alle sykdommer som skyldes defekt i viktige strukturer i 
cellekjernen. 
Figur 22: figuren illustrerer telomerasekomplekset som består av 
proteinene TERT og dyskerin (DKC1), som begge binder spesifikt til TERC. 
Mutasjoner i hver komponent kan lede til bestemte sykdommer. 
Autosomal dominant og X‐bundet Dyskeratosis congenita (DC), 
beinmargssvikt (BMF) og idiopatisk pulmonal fibrose (IPF). 
Figur 23: figuren viser sammenhengen mellom telomerlengde i perifere 
mononukleære blodceller og nivå av oksidativ DNA‐skade (målt i 8‐OH‐
deoxyguansosine). 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VIII. Ordliste 
p53 – tumorsuppressorgen som kontrollerer cellesyklus. Mutasjon eller 
skade av dette vil kunne føre til økt fare for kreft. 
TERT – telomerasens katalytiske subenhet. TERT lager nye TTAGGG‐
sekvenser. 
TRF1 og TRF2 – terminalt restriksjonsfragment, også kalt 
telomerrestriksjonsfragment, 1 og 2. Kan brukes som mål på 
telomerlengde.  
TERC – telomerasens RNA‐komponent. Denne koder for TTAGGG‐
sekvensene.  
p21 – cellesyklusinhibitor som reguleres av p53. Induserer cellesyklusarrest 
ved DNA‐skade.  
CIN – kromosomal instabilietet. Må ikke forveksles med cervical 
intraepitelial neoplasi. 
MYC – regulatorisk gen. Mutert MYC er ofte til stede ved kreft.  
Retinoblastom ‐ tumorsuppressorgen som kontrollerer cellesyklus. 
Mutasjon eller skade av dette vil kunne føre til økt fare for kreft. 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IX. English summary 
The great increase in focus on the effect of telomeres and telomerase on 
human biology, and the fact that this, in a historical perspective, is a 
relatively new field of science, is the background for this thesis.  
Methods and material: the basis for this thesis is a non‐systematic search in 
literature on PubMed in addition to a personal selection of existing, 
relevant articles. 
Telomeres are short sequences of DNA located on the end of human 
chromosomes. They protect the chromosome ends and prevent loss of 
functional DNA. Telomeres are shortened during each cellular divison, and 
when telomeres become critically short, cellular ageing or apoptosis is 
triggered. Telomere shortening is associated with accelerated ageing and 
increased mortality in several diseases, among them cardiovascular, 
autoimmune, and progeroid diseases, Alzheimer’s dementia, cognitive 
failure, paranoid schizophrenia, and cancer.  
The enzyme telomerase is responsible for building telomeres, and can 
therefore inhibit telomere shortening. However, in normal, somatic cells 
telomerase is rarely expressed. On the contrary, in 90 % of cancer, 
telomerase is activated and therefore plays an important role in cancer 
development. In the future, interventions aimed to inhibit and activate 
telomerase are thought to be a method to treat cancer on the one hand, 
and prevent ageing on the other. 
